Ramucirumab
- Generic Name
- Ramucirumab
- Brand Names
- Cyramza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 947687-13-0
- Unique Ingredient Identifier
- D99YVK4L0X
- Background
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and down...
- Indication
Ramucirumab is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel for patients who progress after prior fluoropyrimidine- or platinum-containing chemotherapy. It is indicated, in combination with erlotinib, for the first-line treatment of metastatic no...
- Associated Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Non-Small Cell Lung Cancer, Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Associated Therapies
- -
A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 100
- Registration Number
- NCT06029127
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China
🇨🇳Gansu Provincial Hospital, Lanzhou, Gansu, China
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT06007937
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities), Commack, New York, United States
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 105
- Registration Number
- NCT05999994
- Locations
- 🇧🇪
UCL- Saint Luc, Bruxelles, Belgium
🇫🇷Institut Curie, Paris, France
🇳🇱Prinses Maxima Centrum, Utrecht, Netherlands
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 72
- Registration Number
- NCT05980000
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 305
- Registration Number
- NCT05365581
- Locations
- 🇰🇷
Site KR82003, Seocho-gu, Seoul, Korea, Republic of
🇰🇷Site KR82005, Seodaemun-gu, Seoul, Korea, Republic of
🇰🇷Site KR82001, Guro-gu, Seoul, Korea, Republic of
Quaratusugene Ozeplasmid (Reqorsa) in Combination with Pembrolizumab in Previously Treated Non-Small Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Genprex, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT05062980
- Locations
- 🇺🇸
Moffitt Cancer Center - Magnolia Campus, Tampa, Florida, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸Washington University School of Medicine - Siteman Cancer Center, St. Louis, Missouri, United States
Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT05007769
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
- Conditions
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- ALX Oncology Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT05002127
- Locations
- 🇺🇸
The Oncology Institute of Hope & Innovation, Anaheim, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
AB122 Platform Study
- Conditions
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 715
- Registration Number
- NCT04999761
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Wakayama, Japan
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 30
- Registration Number
- NCT04921904
- Locations
- 🇺🇸
Baylor University Medical Center, Charles A Sammons Cancer Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.